Shots:

• Santhera to receive $49.5M upfront- ~$54.5M as milestones- making the total deal value ~104M. Chiesi to get an exclusive WW rights to develop & commercialize Raxone for LHON and other ophthalmological indications (Ex- the US & Canada) and has an option to fully acquire Santhera’s Raxone business
• The focus of the agreement is to allow Santhera to advance its clinical-stage neuro-muscular and pulmonary programs. The transaction is expected to close in Q3’19
• Raxone (idebenone) is a therapy for visual impairment in adults and adolescents aged ≥12 yrs with LHON and has received ODD in 2017. Additionally- Santhera plans to submit Puldysa's (idebenone) MAA to EMA for DMD

Ref: Santhera | Image: Bianco Lavoro